How many 8-K filings has Lifecore Biomedical, Inc. \De\ filed?

Lifecore Biomedical, Inc. \De\ (LFCR) has 35 8-K (Current Event Report) filings on record, spanning Jan 2024 to Nov 2025.

What is a 8-K filing?

A 8-K is an SEC filing known as "Current Event Report." Filed to announce significant events or material changes such as acquisitions, executive departures, earnings announcements, or bankruptcy filings.

Where can I read Lifecore Biomedical, Inc. \De\ 8-K filings in plain English?

ReadTheFiling provides AI-powered plain-English summaries of all Lifecore Biomedical, Inc. \De\ 8-K filings, including risk assessment, sentiment analysis, and key financial figures.

Lifecore Biomedical, Inc. \De\ (LFCR) — 8-K Filings

All 8-K filings from Lifecore Biomedical, Inc. \De\. Browse 35 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (35)

8-K Filing — Nov 17, 2025
LifeCore Biomedical Reports on Shareholder Vote Matters — Oct 31, 2025 Risk: low
LifeCore Biomedical, Inc. filed an 8-K on October 31, 2025, reporting on matters submitted to a vote of security holders as of October 29, 2025. The filing indi
Lifecore Biomedical Reports Board and Executive Changes — Sep 26, 2025 Risk: medium
On September 22, 2025, Lifecore Biomedical, Inc. reported a change in its board of directors and executive compensation arrangements. The filing indicates a dep
LifeCore Biomedical Changes Certifying Accountant — Aug 18, 2025 Risk: low
LifeCore Biomedical, Inc. (formerly Landec Corp) filed an 8-K on August 18, 2025, reporting a change in its certifying accountant as of August 12, 2025. The com
Lifecore Biomedical Files 8-K — Aug 12, 2025 Risk: low
On August 12, 2025, Lifecore Biomedical, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits.
Lifecore Biomedical Reports Board and Compensation Changes — Jul 18, 2025 Risk: medium
On July 15, 2025, Lifecore Biomedical, Inc. reported a change in its board of directors and executive compensation arrangements. Specifically, the company annou
Lifecore Biomedical Reports Board and Officer Changes — Apr 16, 2025 Risk: medium
On April 11, 2025, Lifecore Biomedical, Inc. reported a change in its board of directors and executive officers. The filing indicates the departure of certain o
Lifecore Biomedical Files 8-K for Shareholder Vote — Apr 10, 2025 Risk: low
On April 10, 2025, Lifecore Biomedical, Inc. filed an 8-K report to announce the submission of matters to a vote of its security holders. The filing does not di
Lifecore Biomedical Files 8-K for Financials — Jan 17, 2025 Risk: low
On January 17, 2025, Lifecore Biomedical, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating potential update
Lifecore Biomedical Files 8-K with Office and Former Name Details — Jan 7, 2025 Risk: low
On January 7, 2025, Lifecore Biomedical, Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 3515 Lyman Boul
Lifecore Biomedical Files 8-K with Material Agreement — Nov 26, 2024 Risk: medium
On November 26, 2024, Lifecore Biomedical, Inc. filed an 8-K report detailing a material definitive agreement. The filing also included Regulation FD disclosure
Lifecore Biomedical Files 8-K — Nov 21, 2024 Risk: low
On November 21, 2024, Lifecore Biomedical, Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 3515 Lyman Bo
LifeCore Biomedical Files 8-K on Shareholder Votes — Nov 8, 2024 Risk: low
LifeCore Biomedical, Inc. filed an 8-K on November 8, 2024, reporting on matters submitted to a vote of security holders as of November 7, 2024. The filing indi
Lifecore Biomedical Files 8-K on Officer/Director Changes — Sep 23, 2024 Risk: medium
On September 23, 2024, Lifecore Biomedical, Inc. filed an 8-K report detailing changes in its board of directors and executive officers. The report also covers
Lifecore Biomedical Relocates Principal Executive Offices — Sep 12, 2024 Risk: low
On September 11, 2024, Lifecore Biomedical, Inc. filed an 8-K report. The filing indicates a change in the company's principal executive offices to 3515 Lyman B
LifeCore Biomedical Files 8-K on Equity Sales & Personnel Changes — Aug 29, 2024 Risk: medium
LifeCore Biomedical, Inc. filed an 8-K on August 28, 2024, reporting on the unregistered sales of equity securities, the departure and election of directors and
Lifecore Biomedical Files 8-K on Financials — Aug 26, 2024 Risk: low
On August 26, 2024, Lifecore Biomedical, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as
Lifecore Biomedical Files 8-K on Corporate Changes — Aug 21, 2024 Risk: medium
On August 15, 2024, Lifecore Biomedical, Inc. filed an 8-K report detailing several significant corporate actions. These include amendments to its articles of i
Lifecore Biomedical Announces Executive and Director Changes — Jul 24, 2024 Risk: medium
On July 18, 2024, Lifecore Biomedical, Inc. reported changes in its executive and director positions. The company announced the appointment of new officers and
Lifecore Biomedical Reports Exit/Disposal Costs — Jul 12, 2024 Risk: medium
On July 8, 2024, Lifecore Biomedical, Inc. filed an 8-K report detailing cost associated with exit or disposal activities. The company, incorporated in Delaware
Lifecore Biomedical Files 8-K: Material Agreement & Officer Changes — Jul 1, 2024 Risk: medium
On June 28, 2024, Lifecore Biomedical, Inc. reported a material definitive agreement and changes in its board and officer composition. The company also disclose
LifeCore Biomedical Faces Delisting Concerns — Jun 7, 2024 Risk: high
LifeCore Biomedical, Inc. (formerly Landec Corp) filed an 8-K on June 7, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or
LifeCore Biomedical Files 8-K: Equity Sales & Officer Changes — May 22, 2024 Risk: low
LifeCore Biomedical, Inc. reported on May 19, 2024, regarding unregistered sales of equity securities and changes in directors and officers. The company also fi
LifeCore Biomedical Files 8-K — May 16, 2024 Risk: low
LifeCore Biomedical, Inc. filed an 8-K on May 16, 2024, to report on other events and financial statements. The company, formerly known as Landec Corp, is incor
Lifecore Biomedical Files 8-K, Notes Listing Rule Concerns — May 14, 2024 Risk: medium
On May 8, 2024, Lifecore Biomedical, Inc. filed an 8-K report detailing a material definitive agreement. The filing also noted a potential delisting or failure
Lifecore Biomedical Files 8-K with Material Agreement — May 8, 2024 Risk: medium
On May 2, 2024, Lifecore Biomedical, Inc. entered into a material definitive agreement. The company also reported on shareholder nominations pursuant to Exchang
Lifecore Biomedical Announces Executive and Director Changes — May 7, 2024 Risk: medium
On May 1, 2024, Lifecore Biomedical, Inc. reported changes in its executive and director positions. The company announced the appointment of a new Chief Financi
Lifecore Biomedical Changes Auditors — Apr 30, 2024 Risk: medium
On April 29, 2024, Lifecore Biomedical, Inc. announced a change in its certifying accountant. The company has dismissed BDO USA, P.A. as its independent registe
LifeCore Biomedical Faces Delisting Concerns — Apr 19, 2024 Risk: high
LifeCore Biomedical, Inc. filed an 8-K on April 19, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The compan
LifeCore Biomedical Files 8-K on Financials — Apr 1, 2024 Risk: low
LifeCore Biomedical, Inc. filed an 8-K on April 1, 2024, reporting on its Results of Operations and Financial Condition. The filing includes financial statement
LifeCore Biomedical Changes Auditors Amidst Accounting Dispute — Mar 26, 2024 Risk: medium
LifeCore Biomedical, Inc. announced on March 20, 2024, a change in its certifying accountant. The company has dismissed PricewaterhouseCoopers LLP and engaged B
Lifecore Biomedical Appoints New Directors, One Departs — Mar 21, 2024 Risk: low
On March 20, 2024, Lifecore Biomedical, Inc. announced the departure of Director David L. Johnson. The company also elected two new directors, Michael J. O'Conn
8-K Filing — Feb 16, 2024
LIFECORE BIOMEDICAL CONFIRMS NASDAQ GLOBAL SELECT MARKET LISTING — Jan 12, 2024
LifeCore Biomedical, Inc. (LFCR) filed an 8-K on January 12, 2024, reporting that its Common Stock is registered on The NASDAQ Global Select Market. This filing
LIFECORE BIOMEDICAL REPORTS MATERIAL AGREEMENT, NEW OBLIGATION — Jan 5, 2024
LifeCore Biomedical, Inc. filed an 8-K on January 5, 2024, reporting events that occurred on December 31, 2023. The filing indicates the company entered into a

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX